Prostate Cancer Mortality Reduction by Prostate-Specific Antigen–Based Screening Adjusted for Nonattendance and Contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC)
- 29 July 2009
- journal article
- research article
- Published by Elsevier in European Urology
- Vol. 56 (4), 584-591
- https://doi.org/10.1016/j.eururo.2009.07.018
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- SECONDARY ANALYSIS OF THE EUROPEAN RANDOMIZED STUDY OF SCREENING FOR PROSTATE CANCER (ERSPC) - EFFECT OF PROSTATE CANCER SCREENING ON THE DEVELOPMENT OF METASTASES AFTER ADJUSTMENT FOR NON-COMPLIANCE AND CONTAMINATIONJournal of Urology, 2009
- Screening and Prostate-Cancer Mortality in a Randomized European StudyNew England Journal of Medicine, 2009
- Feasibility study of adjustment for contamination and non-compliance in a prostate cancer screening trialThe Prostate, 2007
- Contamination by opportunistic screening in the European Randomized Study of Prostate Cancer ScreeningBJU International, 2003
- Lead Times and Overdetection Due to Prostate-Specific Antigen Screening: Estimates From the European Randomized Study of Screening for Prostate CancerJNCI Journal of the National Cancer Institute, 2003
- Effective PSA contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate CancerInternational Journal of Cancer, 2003
- Statistical issues in randomized trials of cancer screeningBMC Medical Research Methodology, 2002
- ADJUSTING FOR NON-COMPLIANCE AND CONTAMINATION IN RANDOMIZED CLINICAL TRIALSStatistics in Medicine, 1997